Commodore Capital
Commodore Capital reported 37 stocks worth $1.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RLAY (16.8%), ELVN (11.6%) and ALKS (9.0%). Compared with Q2 2026, the fund opened new positions in DMRA, SRZN and KRSA, added to IFRX and RLMD, trimmed ALKS, SYRE and AMLX and sold out of TNGX, EYPT and CATX.
Latest filing: what Commodore Capital did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() RLAY Relay Therapeutics Inc | $217M | 16.8% | 12M | No change | 6 of 8 | |
| 2 | ![]() ELVN Enliven Therapeutics Inc | $150M | 11.6% | 3.3M | No change | 8 of 8 | |
| 3 | ![]() ALKS Alkermes PLC | $117M | 9.0% | 2.9M | −125K (−4%) | 8 of 8 | |
| 4 | ![]() ANRO Alto Neuroscience Inc | $69.5M | 5.4% | 2.7M | No change | 4 of 8 | |
| 5 | ![]() SYRE Spyre Therapeutics Inc | $62.3M | 4.8% | 700K | −147K (−17%) | 8 of 8 | |
| 6 | ![]() AMLX Amylyx Pharmaceuticals Inc | $58.2M | 4.5% | 2M | −3.6M (−65%) | 5 of 8 | |
| 7 | ![]() LBRX LB Pharmaceuticals Inc | $49.2M | 3.8% | 1.3M | −218K (−15%) | 5 of 8 | |
| 8 | ![]() DMRA Damora Therapeutics Inc | $41.3M | 3.2% | 1.9M | New position | 1 of 8 | |
| 9 | ![]() COGT Cogent Biosciences Inc | $40.5M | 3.1% | 1.3M | −1.8M (−59%) | 8 of 8 | |
| 10 | ![]() TYRA Tyra Biosciences Inc | $37.7M | 2.9% | 1.7M | −150K (−8%) | 7 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() TNGX Tango Therapeutics Inc | $70.3M | 2.3M |
![]() EYPT Eyepoint Pharmaceuticals Inc | $65.8M | 4.6M |
GALECTO INC | $50.4M | 1.9M |
![]() CATX Perspective Therapeutics Inc | $21.6M | 6.3M |
NUVALENT INC | $12.3M | 100K |
🔒 Free account: see all 7.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Commodore Capital 13F FAQ
What does Commodore Capital own?
Commodore Capital reported 37 stocks worth $1.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RLAY (16.8%), ELVN (11.6%) and ALKS (9.0%). The table above lists every position in the filing (the top 10 without an account).
What did Commodore Capital buy and sell in Q3 2026?
Compared with Q2 2026: 11 new positions, 2 added to, 11 trimmed and 7 sold out. New positions include DMRA, SRZN and KRSA. It sold all of TNGX, EYPT and CATX.
When will Commodore Capital file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Commodore Capital's portfolio worth?
The Q3 2026 filing reports $1.3B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.





















